A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means Endpoints News ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com